同源与异源Covid-19加强疫苗接种
该1-2期开放标签试验在美国10个中心纳入已完成新冠疫苗基础免疫至少12周的成人458例,分别以mRNA-1273(100 μg)、Ad26.COV2.S(5×10^10病毒颗粒)或BNT162b2(30 μg)加强接种,评估安全性、反应原性和体液免疫原性。所有组合中和抗体滴度升高4至73倍,同源加强升高4至20倍,异源加强升高6至73倍,安全性可接受。
要点
- 同源与异源加强接种均使中和抗体滴度升高4至73倍,安全性可接受。
- 同源加强中和抗体升高4至20倍,异源加强升高6至73倍。
- 除同源Ad26.COV2.S加强亚组外,所有组 Spike 特异性T细胞应答均增加。
核心结论
- 同源和异源加强疫苗在完成基础新冠疫苗至少12周的成人中安全性可接受且具有免疫原性。
研究设计与样本
- 1-2期开放标签临床试验,在美国10个中心开展,纳入已完成新冠疫苗基础免疫至少12周且无SARS-CoV-2感染史的成人458例。
- 参与者接受mRNA-1273(100 μg)、Ad26.COV2.S(5×10^10病毒颗粒)或BNT162b2(30 μg)加强接种;154例接受mRNA-1273,150例接受Ad26.COV2.S,153例接受BNT162b2,1例未接受分配疫苗。
- 主要终点为第15天和第29天的安全性、反应原性和体液免疫原性。
主要发现
- 反应原性与基础免疫系列相似,超过半数受者报告注射部位疼痛、不适、头痛或肌痛。
- 所有组合针对SARS-CoV-2 D614G假病毒的中和抗体滴度升高4至73倍,结合抗体滴度升高5至55倍。
- 同源加强使中和抗体滴度升高4至20倍,异源加强升高6至73倍。
- 除同源Ad26.COV2.S加强亚组外,所有组 Spike 特异性T细胞应答均增加;Ad26.COV2.S基础免疫者CD8+ T细胞水平更持久,以Ad26.COV2.S异源加强mRNA疫苗受者显著增加Spike特异性CD8+ T细胞。
关键数值与推荐
- mRNA-1273加强剂量为100 μg。
- Ad26.COV2.S加强剂量为5×10^10病毒颗粒。
- BNT162b2加强剂量为30 μg。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective, breakthrough infections are occurring. Data are needed on the serial use of homologous boosters (same as the primary vaccine) and heterologous boosters (different from the primary vaccine) in fully vaccinated recipients. METHODS: In this phase 1-2, open-label clinical trial conducted at 10 sites in the United States, adults who had completed a Covid-19 vaccine regimen at least 12 weeks earlier and had no reported history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection received a booster injection with one of three vaccines: mRNA-1273 (Moderna) at a dose of 100 μg, Ad26.COV2.S (Johnson & Johnson-Janssen) at a dose of 5×1010 virus particles, or BNT162b2 (Pfizer-BioNTech) at a dose of 30 μg. The primary end points were safety, reactogenicity, and humoral immunogenicity on trial days 15 and 29. RESULTS: Of the 458 participants who were enrolled in the trial, 154 received mRNA-1273, 150 received Ad26.COV2.S, and 153 received BNT162b2 as booster vaccines; 1 participant did not receive the assigned vaccine. Reactogenicity was similar to that reported for the primary series. More than half the recipients reported having injection-site pain, malaise, headache, or myalgia. For all combinations, antibody neutralizing titers against a SARS-CoV-2 D614G pseudovirus increased by a factor of 4 to 73, and binding titers increased by a factor of 5 to 55. Homologous boosters increased neutralizing antibody titers by a factor of 4 to 20, whereas heterologous boosters increased titers by a factor of 6 to 73. Spike-specific T-cell responses increased in all but the homologous Ad26.COV2.S-boosted subgroup. CD8+ T-cell levels were more durable in the Ad26.COV2.S-primed recipients, and heterologous boosting with the Ad26.COV2.S vaccine substantially increased spike-specific CD8+ T cells in the mRNA vaccine recipients. CONCLUSIONS: Homologous and heterologous booster vaccines had an acceptable safety profile and were immunogenic in adults who had completed a primary Covid-19 vaccine regimen at least 12 weeks earlier. (Funded by the National Institute of Allergy and Infectious Diseases; DMID 21-0012 ClinicalTrials.gov number, NCT04889209.).
引用
- Atmar RL, Lyke KE, Deming ME, et al. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022. PMID: 35081293. doi:10.1056/NEJMoa2116414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。